NCT03271632

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Multiple Antigen-specific CAR T Cells For the Treatment of Multiple Myeloma

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Shenzhen Geno-Immune Medical Institute · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The aim of this clinical trial is to assess the feasibility, safety and efficacy of autologous CAR T cell immunotherapy targeting multiple cancer cell surface antigens in relapsed and refractory multiple myeloma patients. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.

Detailed description

Multiple myeloma (MM) is a malignancy of plasma cells, which remains a clinical challenge despite advanced therapeutic interventions including novel molecular therapies and stem cell transplantation (SCT). This trial is to test the safety and efficacy of T cells genetically modified to specifically target several MM surface antigens, including BCMA, CD38, CD56, CD138 or alternative MM surface antigens, based on a multi-CAR T cell immunotherapy approach. Another goal of the study is to investigate the persistence and function of CAR T cells in the body after CAR T cell infusion.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
BIOLOGICAL	CAR T cells	Infusion of multi-CAR T cells

Timeline

• Start date: 2017-07-15
• Primary completion: 2019-12-31
• Completion: 2020-12-31
• First posted: 2017-09-05
• Last updated: 2019-09-19

Locations

2 sites across 1 country: China